Skip to main content

Response Genetics Raises $4M in Private Placement

NEW YORK (GenomeWeb News) – Response Genetics has entered into an agreement to sell $4 million of common stock through a private placement, the Los Angeles-based molecular diagnostics firm said this week.

Response Genetics said that it had inked an agreement with certain funds managed by Lansdowne Partners to acquire 3,057,907 shares of newly issued common stock for $1.30 per share.

The firm did not provide details regarding the use of the proceeds.

Response Genetics undertook a restructuring earlier this year, in which it closed its UK facility and laid off all nine of its employees there. The firm consolidated its services at its CLIA-certified laboratory facilities in Los Angeles and planned to expand its US sales force.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.